Cholecalciferol
FDA-approved product (solution, intravenous).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anemia (phenotype)
- Iron deficiency anemia
- Osteoporosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Vitamin d and analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli23.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cholecalciferol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Flavoxate HydrochlorideExisting use: Dysuria, Prostatitis, Urethritis and 1 more44.3% AI-predicted activityagainst E. coli2 registered studies
- LoxapineExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 2 more44.3% AI-predicted activityagainst E. coli37 registered studies
- PaclitaxelExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 13 more44.2% AI-predicted activityagainst E. coli50+ registered studies
- LifitegrastExisting use: Dry eye syndrome, Eye disease44.2% AI-predicted activityagainst E. coli39 registered studies
- AlvimopanExisting use: Constipation44.2% AI-predicted activityagainst E. coli26 registered studies
- TovorafenibExisting use: Low grade glioma44.1% AI-predicted activityagainst E. coli16 registered studies
- BuprenorphineExisting use: Chronic pain, Drug dependence, Opioid dependence and 4 more44.1% AI-predicted activityagainst E. coli50+ registered studies
- Conivaptan HydrochlorideExisting use: Cardiovascular disease, Heart failure44.1% AI-predicted activityagainst E. coli21 registered studies
- DacomitinibExisting use: Neoplasm, Non-small cell lung carcinoma44.1% AI-predicted activityagainst E. coli50+ registered studies
- CeritinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma44.0% AI-predicted activityagainst E. coli50+ registered studies
- FezolinetantExisting use: Hot flashes44.0% AI-predicted activityagainst E. coli32 registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more44.0% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Vitamin D Inadequacy in Rural Populations, Evaluation of Correction by Food Supplementation
NCT00690417 · start 2007-08
Registered record
- Registry ID
- NCT00690417
- Conditions
- Vitamin D Insufficiency; Vitamin D Deficiency
- Interventions
- Cholecalciferol (vitamin D3)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-08
- Completion
- 2011-08
- Enrolment
- 108
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVitamin D Insufficiency; Vitamin D DeficiencyInterventionCholecalciferol (vitamin D3)PhaseNot applicableRegistry statusCompletedGene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation
NCT00926315 · start 2007-07
Registered record
- Registry ID
- NCT00926315
- Conditions
- Breast Neoplasms; Postmenopausal Disorder
- Interventions
- calcitriol; Calcitriol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2007-07
- Completion
- 2013-12
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Neoplasms; Postmenopausal DisorderInterventioncalcitriol; CalcitriolPhaseNot applicableRegistry statusUnknownEvaluation of Colecalciferol Substitution in Dialysis Patients
NCT00397475 · start 2006-11
Registered record
- Registry ID
- NCT00397475
- Conditions
- RENAL INSUFFICIENCY, CHRONIC; Hyperparathyroidism, Secondary
- Interventions
- Colecalciferol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2007-03
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRENAL INSUFFICIENCY, CHRONIC; Hyperparathyroidism, SecondaryInterventionColecalciferolPhaseNot applicableRegistry statusCompletedVitamin D Deficiency: Bone Loss and Vascular Dysfunction
NCT00235586 · start 2004-04
Registered record
- Registry ID
- NCT00235586
- Conditions
- Postmenopausal Women
- Interventions
- 10 vit. D deficient subjects take vit. D for 3 months.
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-04
- Completion
- 2007-09
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopausal WomenIntervention10 vit. D deficient subjects take vit. D for 3 months.PhaseNot applicableRegistry statusCompletedEfficacy of Calcitriol in Recent Onset Type 1 Diabetes
NCT01120119
Registered record
- Registry ID
- NCT01120119
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Calcitriol
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus, Type 1InterventionCalcitriolPhasePhase 2Registry statusCompleted